In vivo evaluation of the virucidal efficacy of chlorhexidine and povidone-iodine mouthwashes against salivary SARS-CoV-2. A randomized-controlled clinical trial.


Journal

The journal of evidence-based dental practice
ISSN: 1532-3390
Titre abrégé: J Evid Based Dent Pract
Pays: United States
ID NLM: 101083101

Informations de publication

Date de publication:
09 2021
Historique:
received: 20 12 2020
revised: 18 03 2021
accepted: 21 04 2021
entrez: 4 9 2021
pubmed: 5 9 2021
medline: 9 9 2021
Statut: ppublish

Résumé

The oral cavity is potentially high-risk transmitter of COVID-19. Antimicrobial mouthrinses are used in many clinical preprocedural situations for decreasing the risk of cross-contamination in the dental setting. It is important to investigate the efficacy of mouthwash solutions against salivary SARS-CoV-2 in order to reduce the exposure of the dental team during dental procedures. The aim of this in vivo study was to evaluate the efficacy of 2 preprocedural mouthrinses in the reduction of salivary SARS-CoV-2 viral load and to compare the results of the mouthwashes to a control group. In this randomized-controlled clinical trial, studied group comprised laboratory-confirmed COVID-19 positive patients through nasopharyngeal swabs. Participants were divided into 3 groups. For 30 s, the control group mouthrinsed with distilled water, the Chlorhexidine group mouthrinsed with 0.2% Chlorhexidine and the Povidone-iodine group gargled with 1% Povidone-iodine. Saliva samples were collected before and 5 min after mouthwash. SARS-CoV-2 rRT-PCR was then performed for each sample. Evaluation of the efficacy was based on difference in cycle threshold (Ct) value. The analysis of data was carried out using GraphPad Prism version 5 for Windows. Kristal wullis and Paired t-test were used. A probability value of less than 0.05 was regarded as statistically significant. Sixty-one compliant participants (36 female and 25 male) with a mean age 45.3 ± 16.7 years-old were enrolled. A significant difference was noted between the delta Ct of distilled water wash and each of the 2 solutions Chlorhexidine 0.2% (P = .0024) and 1% Povidone-iodine (P = .012). No significant difference was found between the delta Ct of patients using Chlorhexidine 0.2% and 1% Povidone-iodine solutions (P = .24). A significant mean Ct value difference (P < .0001) between the paired samples in Chlorhexidine group (n = 27) and also in Povidone-iodine group (n = 25) (P < .0001) was found. In contrast, no significant difference (P = .566) existed before and after the experiment in the control group (n = 9). Chlorhexidine 0.2% and 1% Povidone-iodine oral solutions are effective preprocedural mouthwashes against salivary SARS-CoV-2 in dental treatments. Their use as a preventive strategy to reduce the spread of COVID-19 during dental practice should be considered.

Identifiants

pubmed: 34479668
pii: S1532-3382(21)00059-2
doi: 10.1016/j.jebdp.2021.101584
pmc: PMC8080510
pii:
doi:

Substances chimiques

Anti-Infective Agents, Local 0
Mouthwashes 0
Povidone-Iodine 85H0HZU99M
Chlorhexidine R4KO0DY52L

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

101584

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Références

Am J Otolaryngol. 2020 Nov - Dec;41(6):102737
pubmed: 32979667
J Dent Res. 2020 May;99(5):481-487
pubmed: 32162995
J Am Dent Assoc. 2019 Dec;150(12):1015-1026.e1
pubmed: 31761015
J Dent Res. 2020 Aug;99(9):1030-1038
pubmed: 32302257
J Hosp Infect. 1998 Apr;38(4):283-95
pubmed: 9602977
J Med Virol. 2020 Jun;92(6):639-644
pubmed: 32141619
Gen Dent. 2001 Nov-Dec;49(6):648-52
pubmed: 12024755
Appl Environ Microbiol. 1995 Aug;61(8):3165-8
pubmed: 7487047
J Am Dent Assoc. 2010 Apr;141(4):415-22
pubmed: 20354090
Clin Oral Investig. 2020 Aug;24(8):2925-2930
pubmed: 32577830
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Endod. 2020 May;46(5):584-595
pubmed: 32273156
J Prosthodont. 2020 Jul;29(6):529-533
pubmed: 32511851
J Am Dent Assoc. 2004 Apr;135(4):429-37
pubmed: 15127864
Oral Oncol. 2020 Jun;105:104724
pubmed: 32317139
J Clin Anesth. 2020 Dec;67:110035
pubmed: 32920346
J Korean Med Sci. 2020 May 25;35(20):e195
pubmed: 32449329
Antiviral Res. 2002 May;54(2):89-97
pubmed: 12062394
Oral Dis. 2022 Apr;28 Suppl 1:908-911
pubmed: 32615642
J Med Virol. 2020 Jul;92(7):903-908
pubmed: 32219885
Clin Oral Investig. 2020 Aug;24(8):2931-2941
pubmed: 32607830
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32317257
J Infect Dis. 2020 Sep 14;222(8):1289-1292
pubmed: 32726430
Intern Med. 2007;46(18):1623-4
pubmed: 17878657
Pathogens. 2021 Mar 01;10(3):
pubmed: 33804294
Br Dent J. 2004 Aug 14;197(3):130-4
pubmed: 15311240
J Occup Environ Med. 2015 May;57(5):501-8
pubmed: 25816216
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32414838
J Hosp Infect. 2020 Mar;104(3):246-251
pubmed: 32035997
Perspect Clin Res. 2010 Apr;1(2):67-9
pubmed: 21829786
Clin Microbiol Infect. 2010 Apr;16(4):317-21
pubmed: 20121827
Lancet. 2020 Feb 22;395(10224):e39
pubmed: 32035510
J Zhejiang Univ Sci B. 2020 May;21(5):361-368
pubmed: 32425001
Restor Dent Endod. 2018 Dec 24;44(1):e3
pubmed: 30834225
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
Dermatology. 1997;195 Suppl 2:29-35
pubmed: 9403252
BMC Infect Dis. 2015 Sep 17;15:375
pubmed: 26381737
Int J Surg. 2020 May;77:206-216
pubmed: 32289472
J Dent Res. 2020 Sep;99(10):1199-1205
pubmed: 32613877
Infect Dis Ther. 2015 Dec;4(4):491-501
pubmed: 26416214
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Ear Nose Throat J. 2021 Apr;100(2_suppl):192S-196S
pubmed: 32951446
Clin Infect Dis. 2020 Jul 28;71(15):841-843
pubmed: 32047895
Ear Nose Throat J. 2020 Nov;99(9):586-593
pubmed: 32520599
Respirology. 2004 Mar;9 Suppl 1:S48-50
pubmed: 14989733
J Craniomaxillofac Surg. 2020 May;48(5):521-526
pubmed: 32303420
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336
Dermatology. 2006;212 Suppl 1:119-23
pubmed: 16490989
Oral Dis. 2021 Apr;27 Suppl 3:655-664
pubmed: 32428372
J Am Dent Assoc. 1995 Dec;126(12):1634-9
pubmed: 7499664
J Clin Diagn Res. 2015 Apr;9(4):ZC52-7
pubmed: 26023644

Auteurs

Rola Elzein (R)

Department of Pediatric Dentistry and Public Dental Health, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon. Electronic address: Roulaelzein@ul.edu.lb.

Fadi Abdel-Sater (F)

Laboratory of Cancer Biology and Cellular Immunology, Department of Biological Sciences, Faculty of Sciences, Lebanese University, Beirut, Lebanon.

Soha Fakhreddine (S)

Infectious Diseases division, Rafik Hariri University Hospital, Beirut, Lebanon.

Pierre Abi Hanna (PA)

Infectious Diseases division, Rafik Hariri University Hospital, Beirut, Lebanon.

Rita Feghali (R)

Department of Laboratory Medicine, Rafik Hariri University Hospital, Beirut, Lebanon.

Hassan Hamad (H)

Medical care Laboratory, Faculty of Public Health IV, Lebanese University, Zahle, Lebanon.

Fouad Ayoub (F)

Department of Forensic Odontology, Human Identification and Anthropology, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH